Application of Heart Rate Variability (HRV) in Congestive Heart Failure (CHF) Detection and Quantification by Chen, Wenhui
Application of Heart Rate Variability 
(HRV) in Congestive Heart Failure 
(CHF) Detection and Quantification
by Wenhui Chen 
Thesis submitted in fulfilment of the requirements for 
the degree of  
Doctor of Philosophy 
under the supervision of Steven Su 
University of Technology Sydney 





Signature removed prior to publication.

Acknowledgements
I would like to express my great appreciation to my supervisor A/Prof. Steven W. Su
for his continual support, guidance, help and encouragement during my PhD study.
A/Prof. Su has brought me into a higher research level for the topic of congestive heart
failure classification, and provided an excellent research platform and brilliant insights
into my research works. It is my honor to have a supervisor who mentors and inspires
me to create and achieve higher targets. His conscientious and meticulous attitude on
research has had a significant influence on my work.
I would like to demonstrate my sincere gratitude to my co-supervisor Dr Steve
S.H. Ling, and external supervisor Prof. Hung T. Nguyen (Swinburne University of
Technology, Australia), for their solid support in congestive heart failure classification
in terms of artificial intelligent algorithm field, which improve my understanding of my
research works.
I am grateful to the other co-supervisors: Prof. Qing Jiang (Sun Yet-sen University,
China), Dr. Guanzheng Liu (Sun Yet-sen University, China), and Prof. Rong Song
(Sun Yet-sen University, China), for their kind help in financial support and mental
encouragement. Prof. Yifan Chen (University of Electronic Science and Technology,
China), and Prof. Chin M. Chow (University of Sydney, Australia), for their professional
and precious comments and suggestions on my research.
Besides, the Australia-China Joint Research Institute for Health Technology and
Innovation (2014), which established by Sun Yat-sen University and University of
Technology Sydney, give me the treasure opportunity and financial support to study in
Australia.
vi
Special thanks to my lovely colleagues in A/Prof. Steven W. Su’s research group,
in particular, Dr. Tao Zhang, Dr. Lin Ye, Dr. Wentian Zhang, Yao Huang, Taoping
Liu, Kairui Guo, and Hairong Yu, for their selfless help and mental support. During
my PhD study, it is a precious life memory working together with them.
I am also lucky to meet many lovely friends: Dr. Ye Shi, Dr. Zhichao Sheng,
Haimin Zhang, Zhiyuan Shi, Dr. Daniel Roxby, for their warm company.
I also wish to express my appreciation to the staff members in the Centre for Health
Technologies, School of biomedical engineering, University of Technology Sydney,
especially to Prof. Joanne Tipper and Dr Gyorgy Hutvagner. It’s a special and
memorizable experience to work with these adorable and inclusive people.
My deepest gratitude goes to my family for their continuous understand and
support.
Thanks to all your encouragement!
Abstract
Congestive heart failure (CHF) is one of the most important cardiovascular syndrome
and end stage of all kinds of heart diseases. Due to high mortality and morbidity,
risk assessment of patient suffering CHF has attracted many attentions. The existing
research about CHF assessment mainly focused on disease detection using ECG signals,
especially with 24-h/5-min heart rate variability (HRV), both in mechanism analysis
and classification. A significant relation between different ECG components and disease
condition had been proved. Furthermore, a good classification performance had been
achieved in CHF detection using HRV. However, there is not much attention focusing
on multilevel assessment of CHF, i.e. disease detection and quantification. Also, sleep
apnea and CHF are two of the most common diseases and interrelated, which are
hard to differentiate from the syndrome. But there is no research in differentiating the
two diseases. Besides, RR intervals are sensitive to physiological activity and rhythm,
increasing unstable analysis and results. Thus, this research will devote to ECG analysis
and multi-level risk assessment model construction to achieve robust, convenient and
accurate CHF detection and quantification, as well as underlying mechanism analysis.
In this research, 116 RR interval data were downloaded from MIT/BIH database,
including 72 normal persons and 44 CHF patients. First, we analyzed 24-h RR intervals
and proposed a series of novel indices of HRV - dynamic indices - to better describing
difference among different risk levels of CHF patients in a day. Then we applied
the decision-tree based support vector machine and backward elimination algorithm
to construct a 4-level risk assessment model for CHF assessment. Results showed a
total accuracy of 96.61% with only two misclassified samples. This demonstrated the
stratifying risk assessment model of CHF in our research has the potential to be a
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reliable and objective prognostic marker for the routine clinical application (especially
daily health nursing) in the future.
Then, we applied 5-min RR intervals into a unsupervised sparse-auto-encoder based
deep learning algorithm to explore CHF detection performance under short cycle in
big data condition. A total of 30592 5-min RR intervals was obtained from 72 healthy
persons and 44 CHF patients. This algorithm first extracts unsupervised features using
a sparse auto-encoder neural network from the raw RR intervals. Then a two layers’
neural network model was constructed. Various hidden node settings were compared
to optimize classification performance. Results showed an accuracy of 72.44% in CHF
detection under the constructed 2-layer neural network, and optimal nodes setting is
(200, 50). This result indicated that short-term RR intervals have the potential for
CHF detection but is sensitive to body condition.
Next, we analyzed different time scale of HRV from 5-min to 24-h to explore optimal
time scale for CHF detection and quantification. Statistical analysis between 3-level
risk-groups was applied under 10 classical HRV measures to evaluate differentiating
power in risk assessment of CHF for the optimal time scale. With the optimal time
length, we used classical classifiers with these classical HRV measures in 3-level risk level
classification of CHF, to prove the usage in risk assessment. The statistical analysis
of HRV measures showed that 2-h RR interval data has the optimal performance
in differentiating three risk levels. The classification performance showed that the
optimal timescale of 2-hour for CHF assessment, yielded an comparable accuracy of
87.88% and 81.13% for classifying the healthy from patients and lower risk from higher
risk patients, respectively. This research demonstrated that the optimal measurement
timescale (2h) has potential in providing convenient and reliable CHF assessment in
the future application, especially in-home monitoring.
Finally, we analyzed whole night Polysomnography (PSG) data to differentiating
congestive heart failure and sleep apnoea patients, which are two of the most tightly
interrelated and common diseases in cardiopulmonary system. Twenty whole night
PSG data from the Sleep Heart Health Study database were included in this study. The
Pan-Tompkins algorithm was applied to the electrocardiograph signal to detect R peaks
of the QRS complex. The whole night R peaks data were then manually checked and
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segmented into 1895 5-minute epochs to calculate three frequency domain and three
nonlinear heart rate variability measures. All these measures were analyzed for their
statistical differences between groups (sleep apnea with and without CHF). Finally, a
binary support vector machine classifier and extreme search method were performed
to construct the model. Results showed that an accuracy of 81.68% was achieved in
distinguishing sleep apnea patients with and without CHF. This indicated that HRV
measures from PSG had the potential to help distinguish sleep apnea patients with
and without CHF reported.
In conclusion, with all these analyses of ECG signals in congestive heart failure
classification, we proved the potential of HRV from ECG in robust, accurate and
convenient congestive heart failure assessment using intelligent methods, which can be
applicated in home-monitoring with wearable ECG measurement equipment.
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